Journey Medical Corp revenue
Journey Medical Corp's revenue was $61.9m in fiscal 2025, up 10.2% on the year before. Since fiscal 2020 ($44.5m) it has grown at a compound 6.8% a year. Over the last twelve months it was $68.2m.
Revenue history
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Qbrexza | $25M | 40.8% | ▼ 0.4% |
| Emrosi | $14.7M | 24.1% | — |
| Accutane | $12.9M | 21.0% | ▼ 33.6% |
| Foam Franchise Products Amzeeq Zilxi | $5.9M | 9.6% | ▼ 11.9% |
| Other Legacy | $2.7M | 4.5% | ▼ 30.9% |
From Journey Medical Corp's 10-K filed March 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Journey Medical Corp | $68.2m | 20.9% | 3.5% |
| Rockwell Medical, Inc. | $69.4m | -21.1% | -2.9% |
| Aytu Biopharma, Inc | $57.6m | -13.3% | -18.8% |
| Aquestive Therapeutics, Inc. | $54.1m | 22.6% | 5.2% |
| Biofrontera Inc. | $46.2m | 17.8% | 16.7% |
| Eton Pharmaceuticals, Inc. | $106m | 81.5% | 53.8% |
Compare with peers
- Rockwell Medical, Inc. revenue
- Aytu Biopharma, Inc revenue
- Aquestive Therapeutics, Inc. revenue
- Biofrontera Inc. revenue
- Eton Pharmaceuticals, Inc. revenue
Head to head: DERM vs RMTIAYTU vs DERMAQST vs DERM
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies